Celldex Therapeutics, Inc. CLDX

CLDX Company Overview

Celldex Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing antibody-based therapeutics and immunology-focused medicines for inflammatory, allergic, and oncologic diseases. The company primarily operates within the biotechnology and biopharmaceutical industries, with its research and development efforts centered on monoclonal antibodies, targeted biologics, and immune pathway modulation. Celldex’s current pipeline is heavily concentrated on mast cell biology and inflammatory disorders, particularly through therapies targeting the KIT receptor and related immune signaling pathways.

The company’s primary value drivers are its clinical-stage drug candidates, especially barzolvolimab, an anti-KIT monoclonal antibody being evaluated across chronic urticaria and other mast cell-mediated diseases. Additional pipeline assets include CDX-622, an interleukin-12/18 cytokine fusion protein, and earlier-stage immunotherapy programs. Celldex historically pursued oncology-focused therapeutics before evolving toward inflammatory and immunologic diseases after pipeline reprioritizations and clinical setbacks in the late 2010s. The company traces its origins to the merger of Medarex subsidiary Celldex Therapeutics and AVANT Immunotherapeutics, with the current corporate structure shaped through subsequent strategic restructurings and asset divestitures.